Pharmacokinetic aspects of retinal drug delivery
Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is appl...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
del Amo, Eva M. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2017transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
52 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Defining ambulatory bouts in free-living activity: Impact of brief stationary periods on bout metrics - Barry, Gillian ELSEVIER, 2015transfer abstract, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:57 ; year:2017 ; pages:134-185 ; extent:52 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.preteyeres.2016.12.001 |
|---|
| Katalog-ID: |
ELV036079294 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV036079294 | ||
| 003 | DE-627 | ||
| 005 | 20230625210705.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.preteyeres.2016.12.001 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000011.pica |
| 035 | |a (DE-627)ELV036079294 | ||
| 035 | |a (ELSEVIER)S1350-9462(16)30063-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 793 |q VZ |
| 082 | 0 | 4 | |a 796 |q VZ |
| 082 | 0 | 4 | |a 570 |q VZ |
| 084 | |a BIODIV |q DE-30 |2 fid | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a del Amo, Eva M. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacokinetic aspects of retinal drug delivery |
| 264 | 1 | |c 2017transfer abstract | |
| 300 | |a 52 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory. | ||
| 520 | |a Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory. | ||
| 650 | 7 | |a Vitreous |2 Elsevier | |
| 650 | 7 | |a Intravitreal |2 Elsevier | |
| 650 | 7 | |a Distribution |2 Elsevier | |
| 650 | 7 | |a Suprachoroidal |2 Elsevier | |
| 650 | 7 | |a Retina |2 Elsevier | |
| 650 | 7 | |a Choroid |2 Elsevier | |
| 650 | 7 | |a Topical |2 Elsevier | |
| 650 | 7 | |a Sub-conjunctival |2 Elsevier | |
| 650 | 7 | |a Clearance |2 Elsevier | |
| 650 | 7 | |a Transport |2 Elsevier | |
| 650 | 7 | |a Pharmacokinetic modeling |2 Elsevier | |
| 700 | 1 | |a Rimpelä, Anna-Kaisa |4 oth | |
| 700 | 1 | |a Heikkinen, Emma |4 oth | |
| 700 | 1 | |a Kari, Otto K. |4 oth | |
| 700 | 1 | |a Ramsay, Eva |4 oth | |
| 700 | 1 | |a Lajunen, Tatu |4 oth | |
| 700 | 1 | |a Schmitt, Mechthild |4 oth | |
| 700 | 1 | |a Pelkonen, Laura |4 oth | |
| 700 | 1 | |a Bhattacharya, Madhushree |4 oth | |
| 700 | 1 | |a Richardson, Dominique |4 oth | |
| 700 | 1 | |a Subrizi, Astrid |4 oth | |
| 700 | 1 | |a Turunen, Tiina |4 oth | |
| 700 | 1 | |a Reinisalo, Mika |4 oth | |
| 700 | 1 | |a Itkonen, Jaakko |4 oth | |
| 700 | 1 | |a Toropainen, Elisa |4 oth | |
| 700 | 1 | |a Casteleijn, Marco |4 oth | |
| 700 | 1 | |a Kidron, Heidi |4 oth | |
| 700 | 1 | |a Antopolsky, Maxim |4 oth | |
| 700 | 1 | |a Vellonen, Kati-Sisko |4 oth | |
| 700 | 1 | |a Ruponen, Marika |4 oth | |
| 700 | 1 | |a Urtti, Arto |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Barry, Gillian ELSEVIER |t Defining ambulatory bouts in free-living activity: Impact of brief stationary periods on bout metrics |d 2015transfer abstract |g Amsterdam [u.a.] |w (DE-627)ELV023844965 |
| 773 | 1 | 8 | |g volume:57 |g year:2017 |g pages:134-185 |g extent:52 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.preteyeres.2016.12.001 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a FID-BIODIV | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_21 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_30 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_130 | ||
| 912 | |a GBV_ILN_147 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2018 | ||
| 936 | b | k | |a 44.00 |j Medizin: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 57 |j 2017 |h 134-185 |g 52 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
a e m d aem aemd |
|---|---|
| matchkey_str |
delamoevamrimpelannakaisaheikkinenemmaka:2017----:hraoieiapcsfeia |
| hierarchy_sort_str |
2017transfer abstract |
| bklnumber |
44.00 |
| publishDate |
2017 |
| allfields |
10.1016/j.preteyeres.2016.12.001 doi GBV00000000000011.pica (DE-627)ELV036079294 (ELSEVIER)S1350-9462(16)30063-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 793 VZ 796 VZ 570 VZ BIODIV DE-30 fid PHARM DE-84 fid 44.00 bkl del Amo, Eva M. verfasserin aut Pharmacokinetic aspects of retinal drug delivery 2017transfer abstract 52 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory. Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory. Vitreous Elsevier Intravitreal Elsevier Distribution Elsevier Suprachoroidal Elsevier Retina Elsevier Choroid Elsevier Topical Elsevier Sub-conjunctival Elsevier Clearance Elsevier Transport Elsevier Pharmacokinetic modeling Elsevier Rimpelä, Anna-Kaisa oth Heikkinen, Emma oth Kari, Otto K. oth Ramsay, Eva oth Lajunen, Tatu oth Schmitt, Mechthild oth Pelkonen, Laura oth Bhattacharya, Madhushree oth Richardson, Dominique oth Subrizi, Astrid oth Turunen, Tiina oth Reinisalo, Mika oth Itkonen, Jaakko oth Toropainen, Elisa oth Casteleijn, Marco oth Kidron, Heidi oth Antopolsky, Maxim oth Vellonen, Kati-Sisko oth Ruponen, Marika oth Urtti, Arto oth Enthalten in Elsevier Science Barry, Gillian ELSEVIER Defining ambulatory bouts in free-living activity: Impact of brief stationary periods on bout metrics 2015transfer abstract Amsterdam [u.a.] (DE-627)ELV023844965 volume:57 year:2017 pages:134-185 extent:52 https://doi.org/10.1016/j.preteyeres.2016.12.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV FID-PHARM SSG-OLC-PHA SSG-OPC-PHA GBV_ILN_21 GBV_ILN_23 GBV_ILN_24 GBV_ILN_30 GBV_ILN_70 GBV_ILN_130 GBV_ILN_147 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2010 GBV_ILN_2015 GBV_ILN_2018 44.00 Medizin: Allgemeines VZ AR 57 2017 134-185 52 045F 610 |
| spelling |
10.1016/j.preteyeres.2016.12.001 doi GBV00000000000011.pica (DE-627)ELV036079294 (ELSEVIER)S1350-9462(16)30063-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 793 VZ 796 VZ 570 VZ BIODIV DE-30 fid PHARM DE-84 fid 44.00 bkl del Amo, Eva M. verfasserin aut Pharmacokinetic aspects of retinal drug delivery 2017transfer abstract 52 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory. Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory. Vitreous Elsevier Intravitreal Elsevier Distribution Elsevier Suprachoroidal Elsevier Retina Elsevier Choroid Elsevier Topical Elsevier Sub-conjunctival Elsevier Clearance Elsevier Transport Elsevier Pharmacokinetic modeling Elsevier Rimpelä, Anna-Kaisa oth Heikkinen, Emma oth Kari, Otto K. oth Ramsay, Eva oth Lajunen, Tatu oth Schmitt, Mechthild oth Pelkonen, Laura oth Bhattacharya, Madhushree oth Richardson, Dominique oth Subrizi, Astrid oth Turunen, Tiina oth Reinisalo, Mika oth Itkonen, Jaakko oth Toropainen, Elisa oth Casteleijn, Marco oth Kidron, Heidi oth Antopolsky, Maxim oth Vellonen, Kati-Sisko oth Ruponen, Marika oth Urtti, Arto oth Enthalten in Elsevier Science Barry, Gillian ELSEVIER Defining ambulatory bouts in free-living activity: Impact of brief stationary periods on bout metrics 2015transfer abstract Amsterdam [u.a.] (DE-627)ELV023844965 volume:57 year:2017 pages:134-185 extent:52 https://doi.org/10.1016/j.preteyeres.2016.12.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV FID-PHARM SSG-OLC-PHA SSG-OPC-PHA GBV_ILN_21 GBV_ILN_23 GBV_ILN_24 GBV_ILN_30 GBV_ILN_70 GBV_ILN_130 GBV_ILN_147 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2010 GBV_ILN_2015 GBV_ILN_2018 44.00 Medizin: Allgemeines VZ AR 57 2017 134-185 52 045F 610 |
| allfields_unstemmed |
10.1016/j.preteyeres.2016.12.001 doi GBV00000000000011.pica (DE-627)ELV036079294 (ELSEVIER)S1350-9462(16)30063-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 793 VZ 796 VZ 570 VZ BIODIV DE-30 fid PHARM DE-84 fid 44.00 bkl del Amo, Eva M. verfasserin aut Pharmacokinetic aspects of retinal drug delivery 2017transfer abstract 52 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory. Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory. Vitreous Elsevier Intravitreal Elsevier Distribution Elsevier Suprachoroidal Elsevier Retina Elsevier Choroid Elsevier Topical Elsevier Sub-conjunctival Elsevier Clearance Elsevier Transport Elsevier Pharmacokinetic modeling Elsevier Rimpelä, Anna-Kaisa oth Heikkinen, Emma oth Kari, Otto K. oth Ramsay, Eva oth Lajunen, Tatu oth Schmitt, Mechthild oth Pelkonen, Laura oth Bhattacharya, Madhushree oth Richardson, Dominique oth Subrizi, Astrid oth Turunen, Tiina oth Reinisalo, Mika oth Itkonen, Jaakko oth Toropainen, Elisa oth Casteleijn, Marco oth Kidron, Heidi oth Antopolsky, Maxim oth Vellonen, Kati-Sisko oth Ruponen, Marika oth Urtti, Arto oth Enthalten in Elsevier Science Barry, Gillian ELSEVIER Defining ambulatory bouts in free-living activity: Impact of brief stationary periods on bout metrics 2015transfer abstract Amsterdam [u.a.] (DE-627)ELV023844965 volume:57 year:2017 pages:134-185 extent:52 https://doi.org/10.1016/j.preteyeres.2016.12.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV FID-PHARM SSG-OLC-PHA SSG-OPC-PHA GBV_ILN_21 GBV_ILN_23 GBV_ILN_24 GBV_ILN_30 GBV_ILN_70 GBV_ILN_130 GBV_ILN_147 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2010 GBV_ILN_2015 GBV_ILN_2018 44.00 Medizin: Allgemeines VZ AR 57 2017 134-185 52 045F 610 |
| allfieldsGer |
10.1016/j.preteyeres.2016.12.001 doi GBV00000000000011.pica (DE-627)ELV036079294 (ELSEVIER)S1350-9462(16)30063-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 793 VZ 796 VZ 570 VZ BIODIV DE-30 fid PHARM DE-84 fid 44.00 bkl del Amo, Eva M. verfasserin aut Pharmacokinetic aspects of retinal drug delivery 2017transfer abstract 52 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory. Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory. Vitreous Elsevier Intravitreal Elsevier Distribution Elsevier Suprachoroidal Elsevier Retina Elsevier Choroid Elsevier Topical Elsevier Sub-conjunctival Elsevier Clearance Elsevier Transport Elsevier Pharmacokinetic modeling Elsevier Rimpelä, Anna-Kaisa oth Heikkinen, Emma oth Kari, Otto K. oth Ramsay, Eva oth Lajunen, Tatu oth Schmitt, Mechthild oth Pelkonen, Laura oth Bhattacharya, Madhushree oth Richardson, Dominique oth Subrizi, Astrid oth Turunen, Tiina oth Reinisalo, Mika oth Itkonen, Jaakko oth Toropainen, Elisa oth Casteleijn, Marco oth Kidron, Heidi oth Antopolsky, Maxim oth Vellonen, Kati-Sisko oth Ruponen, Marika oth Urtti, Arto oth Enthalten in Elsevier Science Barry, Gillian ELSEVIER Defining ambulatory bouts in free-living activity: Impact of brief stationary periods on bout metrics 2015transfer abstract Amsterdam [u.a.] (DE-627)ELV023844965 volume:57 year:2017 pages:134-185 extent:52 https://doi.org/10.1016/j.preteyeres.2016.12.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV FID-PHARM SSG-OLC-PHA SSG-OPC-PHA GBV_ILN_21 GBV_ILN_23 GBV_ILN_24 GBV_ILN_30 GBV_ILN_70 GBV_ILN_130 GBV_ILN_147 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2010 GBV_ILN_2015 GBV_ILN_2018 44.00 Medizin: Allgemeines VZ AR 57 2017 134-185 52 045F 610 |
| allfieldsSound |
10.1016/j.preteyeres.2016.12.001 doi GBV00000000000011.pica (DE-627)ELV036079294 (ELSEVIER)S1350-9462(16)30063-5 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 793 VZ 796 VZ 570 VZ BIODIV DE-30 fid PHARM DE-84 fid 44.00 bkl del Amo, Eva M. verfasserin aut Pharmacokinetic aspects of retinal drug delivery 2017transfer abstract 52 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory. Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory. Vitreous Elsevier Intravitreal Elsevier Distribution Elsevier Suprachoroidal Elsevier Retina Elsevier Choroid Elsevier Topical Elsevier Sub-conjunctival Elsevier Clearance Elsevier Transport Elsevier Pharmacokinetic modeling Elsevier Rimpelä, Anna-Kaisa oth Heikkinen, Emma oth Kari, Otto K. oth Ramsay, Eva oth Lajunen, Tatu oth Schmitt, Mechthild oth Pelkonen, Laura oth Bhattacharya, Madhushree oth Richardson, Dominique oth Subrizi, Astrid oth Turunen, Tiina oth Reinisalo, Mika oth Itkonen, Jaakko oth Toropainen, Elisa oth Casteleijn, Marco oth Kidron, Heidi oth Antopolsky, Maxim oth Vellonen, Kati-Sisko oth Ruponen, Marika oth Urtti, Arto oth Enthalten in Elsevier Science Barry, Gillian ELSEVIER Defining ambulatory bouts in free-living activity: Impact of brief stationary periods on bout metrics 2015transfer abstract Amsterdam [u.a.] (DE-627)ELV023844965 volume:57 year:2017 pages:134-185 extent:52 https://doi.org/10.1016/j.preteyeres.2016.12.001 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV FID-PHARM SSG-OLC-PHA SSG-OPC-PHA GBV_ILN_21 GBV_ILN_23 GBV_ILN_24 GBV_ILN_30 GBV_ILN_70 GBV_ILN_130 GBV_ILN_147 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2010 GBV_ILN_2015 GBV_ILN_2018 44.00 Medizin: Allgemeines VZ AR 57 2017 134-185 52 045F 610 |
| language |
English |
| source |
Enthalten in Defining ambulatory bouts in free-living activity: Impact of brief stationary periods on bout metrics Amsterdam [u.a.] volume:57 year:2017 pages:134-185 extent:52 |
| sourceStr |
Enthalten in Defining ambulatory bouts in free-living activity: Impact of brief stationary periods on bout metrics Amsterdam [u.a.] volume:57 year:2017 pages:134-185 extent:52 |
| format_phy_str_mv |
Article |
| bklname |
Medizin: Allgemeines |
| institution |
findex.gbv.de |
| topic_facet |
Vitreous Intravitreal Distribution Suprachoroidal Retina Choroid Topical Sub-conjunctival Clearance Transport Pharmacokinetic modeling |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Defining ambulatory bouts in free-living activity: Impact of brief stationary periods on bout metrics |
| authorswithroles_txt_mv |
del Amo, Eva M. @@aut@@ Rimpelä, Anna-Kaisa @@oth@@ Heikkinen, Emma @@oth@@ Kari, Otto K. @@oth@@ Ramsay, Eva @@oth@@ Lajunen, Tatu @@oth@@ Schmitt, Mechthild @@oth@@ Pelkonen, Laura @@oth@@ Bhattacharya, Madhushree @@oth@@ Richardson, Dominique @@oth@@ Subrizi, Astrid @@oth@@ Turunen, Tiina @@oth@@ Reinisalo, Mika @@oth@@ Itkonen, Jaakko @@oth@@ Toropainen, Elisa @@oth@@ Casteleijn, Marco @@oth@@ Kidron, Heidi @@oth@@ Antopolsky, Maxim @@oth@@ Vellonen, Kati-Sisko @@oth@@ Ruponen, Marika @@oth@@ Urtti, Arto @@oth@@ |
| publishDateDaySort_date |
2017-01-01T00:00:00Z |
| hierarchy_top_id |
ELV023844965 |
| dewey-sort |
3610 |
| id |
ELV036079294 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV036079294</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625210705.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.preteyeres.2016.12.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000011.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV036079294</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1350-9462(16)30063-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">793</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">796</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">PHARM</subfield><subfield code="q">DE-84</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">del Amo, Eva M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacokinetic aspects of retinal drug delivery</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">52</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Vitreous</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Intravitreal</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Distribution</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Suprachoroidal</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Retina</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Choroid</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Topical</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sub-conjunctival</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clearance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Transport</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmacokinetic modeling</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rimpelä, Anna-Kaisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heikkinen, Emma</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kari, Otto K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ramsay, Eva</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lajunen, Tatu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schmitt, Mechthild</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pelkonen, Laura</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bhattacharya, Madhushree</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Richardson, Dominique</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Subrizi, Astrid</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Turunen, Tiina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reinisalo, Mika</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Itkonen, Jaakko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Toropainen, Elisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Casteleijn, Marco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kidron, Heidi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Antopolsky, Maxim</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vellonen, Kati-Sisko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ruponen, Marika</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Urtti, Arto</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Barry, Gillian ELSEVIER</subfield><subfield code="t">Defining ambulatory bouts in free-living activity: Impact of brief stationary periods on bout metrics</subfield><subfield code="d">2015transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV023844965</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:57</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:134-185</subfield><subfield code="g">extent:52</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.preteyeres.2016.12.001</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-PHARM</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_21</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_30</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_130</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.00</subfield><subfield code="j">Medizin: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">57</subfield><subfield code="j">2017</subfield><subfield code="h">134-185</subfield><subfield code="g">52</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
del Amo, Eva M. |
| spellingShingle |
del Amo, Eva M. ddc 610 ddc 793 ddc 796 ddc 570 fid BIODIV fid PHARM bkl 44.00 Elsevier Vitreous Elsevier Intravitreal Elsevier Distribution Elsevier Suprachoroidal Elsevier Retina Elsevier Choroid Elsevier Topical Elsevier Sub-conjunctival Elsevier Clearance Elsevier Transport Elsevier Pharmacokinetic modeling Pharmacokinetic aspects of retinal drug delivery |
| authorStr |
del Amo, Eva M. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV023844965 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 793 - Indoor games & amusements 796 - Athletic & outdoor sports & games 570 - Life sciences; biology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 793 VZ 796 VZ 570 VZ BIODIV DE-30 fid PHARM DE-84 fid 44.00 bkl Pharmacokinetic aspects of retinal drug delivery Vitreous Elsevier Intravitreal Elsevier Distribution Elsevier Suprachoroidal Elsevier Retina Elsevier Choroid Elsevier Topical Elsevier Sub-conjunctival Elsevier Clearance Elsevier Transport Elsevier Pharmacokinetic modeling Elsevier |
| topic |
ddc 610 ddc 793 ddc 796 ddc 570 fid BIODIV fid PHARM bkl 44.00 Elsevier Vitreous Elsevier Intravitreal Elsevier Distribution Elsevier Suprachoroidal Elsevier Retina Elsevier Choroid Elsevier Topical Elsevier Sub-conjunctival Elsevier Clearance Elsevier Transport Elsevier Pharmacokinetic modeling |
| topic_unstemmed |
ddc 610 ddc 793 ddc 796 ddc 570 fid BIODIV fid PHARM bkl 44.00 Elsevier Vitreous Elsevier Intravitreal Elsevier Distribution Elsevier Suprachoroidal Elsevier Retina Elsevier Choroid Elsevier Topical Elsevier Sub-conjunctival Elsevier Clearance Elsevier Transport Elsevier Pharmacokinetic modeling |
| topic_browse |
ddc 610 ddc 793 ddc 796 ddc 570 fid BIODIV fid PHARM bkl 44.00 Elsevier Vitreous Elsevier Intravitreal Elsevier Distribution Elsevier Suprachoroidal Elsevier Retina Elsevier Choroid Elsevier Topical Elsevier Sub-conjunctival Elsevier Clearance Elsevier Transport Elsevier Pharmacokinetic modeling |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
a k r akr e h eh o k k ok okk e r er t l tl m s ms l p lp m b mb d r dr a s as t t tt m r mr j i ji e t et m c mc h k hk m a ma k s v ksv m r mr a u au |
| hierarchy_parent_title |
Defining ambulatory bouts in free-living activity: Impact of brief stationary periods on bout metrics |
| hierarchy_parent_id |
ELV023844965 |
| dewey-tens |
610 - Medicine & health 790 - Sports, games & entertainment 570 - Life sciences; biology |
| hierarchy_top_title |
Defining ambulatory bouts in free-living activity: Impact of brief stationary periods on bout metrics |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV023844965 |
| title |
Pharmacokinetic aspects of retinal drug delivery |
| ctrlnum |
(DE-627)ELV036079294 (ELSEVIER)S1350-9462(16)30063-5 |
| title_full |
Pharmacokinetic aspects of retinal drug delivery |
| author_sort |
del Amo, Eva M. |
| journal |
Defining ambulatory bouts in free-living activity: Impact of brief stationary periods on bout metrics |
| journalStr |
Defining ambulatory bouts in free-living activity: Impact of brief stationary periods on bout metrics |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 700 - Arts & recreation 500 - Science |
| recordtype |
marc |
| publishDateSort |
2017 |
| contenttype_str_mv |
zzz |
| container_start_page |
134 |
| author_browse |
del Amo, Eva M. |
| container_volume |
57 |
| physical |
52 |
| class |
610 610 DE-600 610 VZ 793 VZ 796 VZ 570 VZ BIODIV DE-30 fid PHARM DE-84 fid 44.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
del Amo, Eva M. |
| doi_str_mv |
10.1016/j.preteyeres.2016.12.001 |
| dewey-full |
610 793 796 570 |
| title_sort |
pharmacokinetic aspects of retinal drug delivery |
| title_auth |
Pharmacokinetic aspects of retinal drug delivery |
| abstract |
Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory. |
| abstractGer |
Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory. |
| abstract_unstemmed |
Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV FID-PHARM SSG-OLC-PHA SSG-OPC-PHA GBV_ILN_21 GBV_ILN_23 GBV_ILN_24 GBV_ILN_30 GBV_ILN_70 GBV_ILN_130 GBV_ILN_147 GBV_ILN_2005 GBV_ILN_2007 GBV_ILN_2008 GBV_ILN_2010 GBV_ILN_2015 GBV_ILN_2018 |
| title_short |
Pharmacokinetic aspects of retinal drug delivery |
| url |
https://doi.org/10.1016/j.preteyeres.2016.12.001 |
| remote_bool |
true |
| author2 |
Rimpelä, Anna-Kaisa Heikkinen, Emma Kari, Otto K. Ramsay, Eva Lajunen, Tatu Schmitt, Mechthild Pelkonen, Laura Bhattacharya, Madhushree Richardson, Dominique Subrizi, Astrid Turunen, Tiina Reinisalo, Mika Itkonen, Jaakko Toropainen, Elisa Casteleijn, Marco Kidron, Heidi Antopolsky, Maxim Vellonen, Kati-Sisko Ruponen, Marika Urtti, Arto |
| author2Str |
Rimpelä, Anna-Kaisa Heikkinen, Emma Kari, Otto K. Ramsay, Eva Lajunen, Tatu Schmitt, Mechthild Pelkonen, Laura Bhattacharya, Madhushree Richardson, Dominique Subrizi, Astrid Turunen, Tiina Reinisalo, Mika Itkonen, Jaakko Toropainen, Elisa Casteleijn, Marco Kidron, Heidi Antopolsky, Maxim Vellonen, Kati-Sisko Ruponen, Marika Urtti, Arto |
| ppnlink |
ELV023844965 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.preteyeres.2016.12.001 |
| up_date |
2024-07-06T19:14:50.056Z |
| _version_ |
1803858256915857408 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV036079294</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625210705.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2017 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.preteyeres.2016.12.001</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000011.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV036079294</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1350-9462(16)30063-5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">793</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">796</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">PHARM</subfield><subfield code="q">DE-84</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">del Amo, Eva M.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Pharmacokinetic aspects of retinal drug delivery</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2017transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">52</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Drug delivery to the posterior eye segment is an important challenge in ophthalmology, because many diseases affect the retina and choroid leading to impaired vision or blindness. Currently, intravitreal injections are the method of choice to administer drugs to the retina, but this approach is applicable only in selected cases (e.g. anti-VEGF antibodies and soluble receptors). There are two basic approaches that can be adopted to improve retinal drug delivery: prolonged and/or retina targeted delivery of intravitreal drugs and use of other routes of drug administration, such as periocular, suprachoroidal, sub-retinal, systemic, or topical. Properties of the administration route, drug and delivery system determine the efficacy and safety of these approaches. Pharmacokinetic and pharmacodynamic factors determine the required dosing rates and doses that are needed for drug action. In addition, tolerability factors limit the use of many materials in ocular drug delivery. This review article provides a critical discussion of retinal drug delivery, particularly from the pharmacokinetic point of view. This article does not include an extensive review of drug delivery technologies, because they have already been reviewed several times recently. Instead, we aim to provide a systematic and quantitative view on the pharmacokinetic factors in drug delivery to the posterior eye segment. This review is based on the literature and unpublished data from the authors' laboratory.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Vitreous</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Intravitreal</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Distribution</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Suprachoroidal</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Retina</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Choroid</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Topical</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Sub-conjunctival</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Clearance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Transport</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pharmacokinetic modeling</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Rimpelä, Anna-Kaisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heikkinen, Emma</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kari, Otto K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ramsay, Eva</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lajunen, Tatu</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schmitt, Mechthild</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pelkonen, Laura</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bhattacharya, Madhushree</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Richardson, Dominique</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Subrizi, Astrid</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Turunen, Tiina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Reinisalo, Mika</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Itkonen, Jaakko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Toropainen, Elisa</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Casteleijn, Marco</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kidron, Heidi</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Antopolsky, Maxim</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Vellonen, Kati-Sisko</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ruponen, Marika</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Urtti, Arto</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Barry, Gillian ELSEVIER</subfield><subfield code="t">Defining ambulatory bouts in free-living activity: Impact of brief stationary periods on bout metrics</subfield><subfield code="d">2015transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV023844965</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:57</subfield><subfield code="g">year:2017</subfield><subfield code="g">pages:134-185</subfield><subfield code="g">extent:52</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.preteyeres.2016.12.001</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-PHARM</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_21</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_30</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_130</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_147</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2007</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2008</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2010</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2015</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2018</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.00</subfield><subfield code="j">Medizin: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">57</subfield><subfield code="j">2017</subfield><subfield code="h">134-185</subfield><subfield code="g">52</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.398546 |